期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿托伐他汀和烟酸缓释片联用治疗老年混合型高脂血症疗效观察 被引量：3

下载PDF
导出
摘要 目的观察阿托伐他汀联用烟酸缓释片治疗老年混合型高脂血症的疗效与安全性。方法将符合入选条件的43例患者随机分为观察组22例和对照组21例,观察组采用阿托伐他汀10mg/d+烟酸缓释片500mg/d,po;对照组单用阿托伐他汀10mg/d,po,疗程3个月。结果治疗3个月后两组血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)的水平均有不同程度的改善,TC、LDL-C降低(P<0.01),但观察组的TC、LDL-C降低效果更为明显;达标率明显提高(观察组的TC、LDL-C达标率为77.27%和63.64%,对照组为66.67%和52.38%,P<0.01);观察组TG降低、HDL-C升高(P<0.01及P<0.05)。未见明显不良反应。结论阿托伐他汀、烟酸缓释片联用治疗老年混合型高脂血症较单用阿托伐他汀更有效、调脂更全面,且具有良好的安全性和耐受性。
作者 李云飞 孙艳霞
机构地区 空军汉口王家墩干休所 湖北武警总医院心内科
出处 《解放军保健医学杂志》 2008年第2期126-127,共2页 Journal Of Health Care And Medicine in Chinese Pla
关键词 高脂蛋白血症 阿托伐他汀 烟酸缓释片
分类号 R541 [医药卫生—心血管疾病]
  • 相关文献

参考文献4

二级参考文献24

  • 1[10]Murdock D K, Murdock A K, Murkock R W, et al . Longterm safety and efficacy of combination gemfibrozil and HMGCoA reductase inhibitors for the treatment of mixed lipid disorders[J]. Am Heart J, 1999,138(1 Pt 1):151-155.
  • 2[11]Iliadis E A, Rosenson R S. Long-term safety of pravastatingemfibrozil therapy in mixed hyperlipidemia[J]. Clin Cardiol,1999,22 (1): 25-28.
  • 3[12]Pauciullo P, Borgnino C, Panletti R, et al. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidemia ( FACT study ) [ J ].Atherosclerosis, 2001,150(2) :429-436.
  • 4[1]Neaton J D, Wentworth D. Serum cholesterol, blood presure,cigarette smoking, and death from coronary heart disease.Overall findings and differences by age for 316 099 white men.Multiple Risk Factor Intervention Trial Research Group[J].Arch Intern Med, 1992,152 (1): 56-64.
  • 5[2]Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in4 444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study[J]. Lancet, 1994,344(8934): 1383-1389.
  • 6[4]The Long-Term Intervention with Pravastatin in Ischemic Disease(LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels[J].N Engl J Med, 1998,339(19) :1349-1357.
  • 7[5]Fric M H, Elo O, Haapa K, et al . Helsinki Heart Study:primary-prevertion trial with gemfibrzil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease[J]. N Engl J Med, 1987,317(20) :1237-1245.
  • 8[6]Rubins H B, Robins S J, Collins D, et al . Gemfibrozil for the secondary prevention or coronary heart disease in men with olw levels of high density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Trial Study Group[J].N Engl J Med, 1999,341(6) :410-418.
  • 9[7]Canner P L, Berge K G, Wenger N K, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin[J]. J Am Coll Cardiol, 1986,8(6): 1245-1255.
  • 10[8]Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program(NCEP)expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Panel Ⅲ)[J].JAMA, 2001,285(19): 2486-2497.

共引文献202

同被引文献28

引证文献3

二级引证文献11

解放军保健医学杂志
2008年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部